At the end of June, Onyx Pharmaceuticals, Inc. announced that it had rejected an offer from Amgen, Inc. that valued the company at $120 per share, or about $8.8 billion.
http://www.insidermonkey.com/blog/amgen-inc-amgn-astrazeneca-plc-adr-azn-whats-the-big-deal-about-onyx-pharmaceuticals-inc-onxx-anyway-227252/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+InsiderMonkey+%28Insider+Monkey%29
http://www.insidermonkey.com/blog/amgen-inc-amgn-astrazeneca-plc-adr-azn-whats-the-big-deal-about-onyx-pharmaceuticals-inc-onxx-anyway-227252/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+InsiderMonkey+%28Insider+Monkey%29
No comments:
Post a Comment